Testing the metabotropic glutamate receptor theory in fragile X syndrome: a randomized, placebo-controlled, proof-of-concept study of AFQ056, a novel, sub-type selective mGluR5 inhibitor
Testing the metabotropic glutamate receptor theory in fragile X syndrome: a randomized, placebo-controlled, proof-of-concept study of AFQ056, a novel, sub-type selective mGluR5 inhibitor. American Society of Human Genetics 2010. 2010.